XML 49 R12.htm IDEA: XBRL DOCUMENT v3.8.0.1
Inventory
12 Months Ended
Dec. 29, 2017
Inventory Disclosure [Abstract]  
Inventory
INVENTORY
Inventory consisted of the following (in thousands):
 
December 31,
 
2017
 
2016
Raw materials
$
498

 
$
863

Work in process
3,997

 
2,343

Finished goods
2,854

 
738

Total
$
7,349

 
$
3,944

 
 
 
 
Balance Sheet classification:
 
 
 
Inventory
$
6,657

 
$
3,338

Other long-term assets
692

 
606

Total
$
7,349

 
$
3,944


A portion of the manufacturing costs for inventory was incurred prior to regulatory approval of CABOMETYX and COMETRIQ and therefore was expensed as research and development costs when those costs were incurred, rather than capitalized as inventory. Write-downs related to excess and expiring inventory are charged to either Cost of goods sold or the cost of supplied product included in Collaboration revenues. Such write-downs were $1.2 million, $0.5 million and $1.2 million for the years ended December 31, 2017, 2016 and 2015, respectively.
Inventory expected to be used or sold in periods more than 12 months from the date presented is classified as Other long-term assets on the accompanying Consolidated Balance Sheets. As of December 31, 2017, the non-current portion of inventory consisted of finished goods. As of December 31, 2016, the non-current portion of inventory consisted of raw materials and a portion of the active pharmaceutical ingredient that was included in work in process inventories.